Aptose Biosciences (TSE:APS) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Aptose Biosciences has launched the TUSCANY Phase 1/2 study to test a new triplet therapy for newly diagnosed acute myeloid leukemia (AML) patients. This innovative treatment combines tuspetinib with azacitidine and venetoclax, aiming to offer an effective frontline therapy for AML patients who cannot undergo intensive chemotherapy. The trial is being conducted across several sites in the United States, with potential to impact a broad range of AML cases.
For further insights into TSE:APS stock, check out TipRanks’ Stock Analysis page.
